CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Charles River Laboratories International, Inc.

Stocks

CRL

US1598641074

Market Closed - NYSE Other stock markets 21:00:02 21/07/2026 BST			5-day change	1st Jan Change
219.40 ^USD	-0.14%		-5.11%	+9.99%

07-20	Analyst recommendations: Global Payments, Charles Schwab, US Bancorp, Datadog, Netflix…
07-13	BofA Adjusts Price Target on Charles River Laboratories International to $264 From $220	MT

Transcript : Charles River Laboratories International, Inc. Presents at 46th Annual William Blair Growth Stock Conference, Jun-02-2026 10

Published on 06/02/2026 at 10:26 pm BST

S&P Capital IQ

Add MarketScreener to your sources

Presenter Speech
Max Smock (Analysts)

All right. Good morning, everyone. Thanks for joining us for the management presentation here. My name is Max Smock, and I'm the research analyst here at William

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Add MarketScreener to your sources

Latest news about Charles River Laboratories International, Inc.

07-20	Analyst recommendations: Global Payments, Charles Schwab, US Bancorp, Datadog, Netflix…
07-13	BofA Adjusts Price Target on Charles River Laboratories International to $264 From $220	MT
07-13	Baird Adjusts Charles River Laboratories International Price Target to $255 From $213, Maintains Outperform Rating	MT
07-13	Charles River Laboratories to Provide Cell Sequencing Services to Arovella Therapeutics	MT
07-13	Charles River Provides Ngs Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches	CI
07-13	Mizuho Adjusts Price Target on Charles River Laboratories International to $230 From $192, Maintains Neutral Rating	MT
07-09	Morgan Stanley Adjusts Price Target on Charles River Laboratories International to $260 From $220	MT
07-07	Evercore ISI Adjusts Price Target on Charles River Laboratories International to $260 From $220	MT
07-01	Charles River Laboratories International Insider Sold Shares Worth $16,875,000, According to a Recent SEC Filing	MT
07-01	Argus Raises Price Target on Charles River Laboratories International to $250 From $200, Maintains Buy Rating	MT
06-18	Charles River Laboratories International, Inc. and Eli Lilly and Company Enter Collaboration to Optimize Ai/Ml Platform Through Nonclinical Testing Expertise	CI
06-18	Rothschild & Co Redburn Adjusts Charles River Laboratories International PT to $241 From $230, Maintains Buy Rating	MT
06-17	Charles River Laboratories Shares Rise After Morgan Stanley Upgrade	MT
06-17	Morgan Stanley Upgrades Charles River Laboratories International to Overweight From Equal Weight, Adjusts PT to $220 From $185	MT
06-05	Charles River Laboratories Has Potential to Outperform in 2H 2026, RBC Says	MT